Q3 2018 EPS Estimates for Dicerna Pharmaceuticals Inc (DRNA) Raised by Analyst
Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) – Equities research analysts at SunTrust Banks increased their Q3 2018 EPS estimates for Dicerna Pharmaceuticals in a research note issued to investors on Monday, August 13th. SunTrust Banks analyst E. Nash now anticipates that the biopharmaceutical company will post earnings per share of ($0.27) for the quarter, up from their previous estimate of ($0.28). SunTrust Banks also issued estimates for Dicerna Pharmaceuticals’ Q4 2018 earnings at ($0.26) EPS, FY2018 earnings at ($1.09) EPS, Q1 2019 earnings at ($0.30) EPS, Q2 2019 earnings at ($0.27) EPS, Q3 2019 earnings at ($0.31) EPS, Q4 2019 earnings at ($0.31) EPS, FY2019 earnings at ($1.15) EPS, FY2020 earnings at ($0.93) EPS, FY2021 earnings at ($0.91) EPS and FY2022 earnings at ($0.63) EPS.
DRNA has been the topic of several other reports. BidaskClub raised Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, August 10th. ValuEngine lowered Dicerna Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 2nd. HC Wainwright raised Dicerna Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $21.00 price target on the stock in a research report on Wednesday. Evercore ISI reissued an “outperform” rating and set a $17.00 price target (up from $14.00) on shares of Dicerna Pharmaceuticals in a research report on Friday, April 20th. Finally, Chardan Capital reissued a “hold” rating and set a $14.50 price target on shares of Dicerna Pharmaceuticals in a research report on Monday, August 13th. One analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $14.54.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last released its earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.68) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by ($0.26). The business had revenue of $1.55 million for the quarter, compared to analysts’ expectations of $1.79 million. Dicerna Pharmaceuticals had a negative net margin of 1,642.81% and a negative return on equity of 97.39%.
In related news, Director Dennis Langer sold 14,531 shares of the company’s stock in a transaction that occurred on Wednesday, August 15th. The stock was sold at an average price of $16.00, for a total transaction of $232,496.00. Following the sale, the director now directly owns 29,064 shares of the company’s stock, valued at approximately $465,024. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 19.85% of the company’s stock.
Several hedge funds have recently bought and sold shares of DRNA. Artal Group S.A. acquired a new stake in Dicerna Pharmaceuticals in the first quarter worth $4,063,000. Goldman Sachs Group Inc. increased its position in Dicerna Pharmaceuticals by 84.2% in the fourth quarter. Goldman Sachs Group Inc. now owns 194,198 shares of the biopharmaceutical company’s stock worth $1,754,000 after buying an additional 88,778 shares during the period. Millennium Management LLC increased its position in Dicerna Pharmaceuticals by 142.8% in the fourth quarter. Millennium Management LLC now owns 66,907 shares of the biopharmaceutical company’s stock worth $604,000 after buying an additional 39,348 shares during the period. Spark Investment Management LLC acquired a new stake in Dicerna Pharmaceuticals in the first quarter worth $1,386,000. Finally, Citadel Advisors LLC acquired a new stake in Dicerna Pharmaceuticals in the first quarter worth $1,632,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.
Dicerna Pharmaceuticals Company Profile
Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of rare, viral infectious, chronic liver, and cardiovascular diseases. Its development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and DCR-PCSK9 to treat hypercholesterolemia.
Recommended Story: Investing in Growth Stocks
Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.